Chinese drug quality audits are evaluations conducted to ensure pharmaceutical products meet regulatory standards. These audits assess manufacturing processes, compliance with Good Manufacturing Practices (GMP), and product safety. They aim to maintain high-quality drug production, protect public health, and ensure that products... Read More
In China, drug quality audits are primarily conducted by the National Medical Products Administration (NMPA), which oversees the regulation and supervision of pharmaceuticals. Additionally, local provincial and municipal drug regulatory authorities assist in ensuring compliance with national standards, conducting inspections, and enforcing... Read More
A Chinese drug quality audit ensures compliance with regulatory standards, verifies the safety and efficacy of pharmaceutical products, and maintains public health. It involves evaluating manufacturing processes, quality control systems, and documentation. The audit aims to identify deficiencies, enforce corrective actions, and... Read More
Drug quality audits in China focus on assessing a company’s internal quality systems and compliance with established standards, often conducted by the company itself or third parties. In contrast, GMP inspections are regulatory evaluations by government authorities to ensure compliance with Good... Read More
A Chinese drug quality audit involves key steps: preparation and planning, document review, on-site inspection, evaluation of manufacturing processes, verification of compliance with Good Manufacturing Practices (GMP), assessment of quality control systems, interviews with staff, identification of non-compliance issues, corrective action recommendations,... Read More
Chinese drug quality audits apply to facilities involved in the manufacturing, processing, packaging, and labeling of pharmaceuticals. This includes active pharmaceutical ingredient (API) producers, finished dosage form manufacturers, contract manufacturing organizations, and any facility involved in the supply chain that impacts drug... Read More
During a Chinese drug quality audit, essential documents include the drug manufacturing license, GMP certificates, quality control records, batch production records, standard operating procedures, raw material specifications, stability study data, deviation reports, corrective action plans, and personnel training records. These ensure compliance... Read More
Chinese drug quality audits are typically conducted annually by the National Medical Products Administration (NMPA). However, the frequency can vary based on risk assessments, with more frequent inspections for high-risk facilities or products. Additionally, unannounced inspections may occur to ensure compliance with... Read More
Common issues in Chinese drug quality audits include inadequate documentation, non-compliance with Good Manufacturing Practices (GMP), insufficient staff training, poor quality control procedures, contamination risks, improper storage conditions, lack of traceability, and inconsistent batch records. These issues can compromise drug safety, efficacy,... Read More
In Chinese drug quality audits, non-conformances are addressed through corrective and preventive actions (CAPA). Companies must investigate root causes, implement corrective measures, and document actions taken. Regulatory authorities may conduct follow-up inspections to ensure compliance. Continuous monitoring and staff training are emphasized... Read More